New York is currently home to 4446 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)
Recruiting
AT148007 is a Phase 1, open-label, multicenter, safety, pharmacokinetic, pharmacodynamic study of ALX148 in combination with enfortumab vedotin and/or other anticancer therapies in subjects with urothelial carcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Bladder Cancer, Urothelial Carcinoma
Treatment With Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI
Recruiting
The objective of the proposed work is to determine whether administration for 12 months of romosozumab (evenity) followed by 12 months of denosumab (prolia) will maintain bone mass at the knee in subjects with chronic SCI.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/21/2024
Locations: James J. Peters VA Medical Center, Bronx, New York
Conditions: Osteoporosis, Spinal Cord Injuries
Prospective Collection of PillCam SB3 Videos and Raw Data Files for Future Developments (SODA)
Recruiting
Observational, Multicenter, Post-market, Minimal risk, Prospective data collection of PillCam SB3 videos (including PillCam reports) and raw data files and optional collection of Eneteroscopy reports
Gender:
ALL
Ages:
All
Trial Updated:
03/20/2024
Locations: Albany Gastroenterology Consultants, Albany, New York
Conditions: Small Intestine Disease, Small Intestine Cancer, Small Intestinal Ulcer Bleeding, Small Intestine Obstruction, Small Intestine Adenocarcinoma, Small Intestine Polyp
Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances
Recruiting
This is a multicenter, open-label study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon in treating sleep disturbances in pediatric and adult participants with ASD.
Gender:
ALL
Ages:
Between 2 years and 65 years
Trial Updated:
03/19/2024
Locations: Vanda Investigational Site, Staten Island, New York
Conditions: Autism Spectrum Disorder, Sleep Disorder, Neurological Disorder, Sleep Disturbance
A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Recruiting
This is an open-label, dose escalation study to evaluate the safety, toxicity, and pharmacokinetics (PK) as well as preliminary efficacy of BTX-A51 capsules in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The study will be done in three parts. Part 1a (Monotherapy Dose Escalation) of this study is designed to determine the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of orally administered BTX-A51 in up to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis
Recruiting
To investigate the safety and efficacy of tradipitant versus placebo in relieving nausea and other symptoms of gastroparesis.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/19/2024
Locations: Vanda Investigational Site, Brooklyn, New York
Conditions: Idiopathic Gastroparesis, Diabetic Gastroparesis, Gastroparesis
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
Recruiting
This research study is comparing two standard of care treatment options based on blood test results for participants who have metastatic colon cancer. The names of the potential treatments involved in this study are: * Active surveillance * FOLFIRI treatment * Nivolumab treatment * Encorafenib/Binimetinib/Cetuximab treatment * Trastuzumab + Pertuzumab
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Metastatic Colon Cancer, Stage III Colon Cancer
Metastatic Tumor Research and Outcomes Network
Recruiting
The registry aims to collect patient information such as patient demographics, co-morbidities, clinical, diagnostic, and therapeutic data, as well as information on adverse events and HRQOL outcomes specific for patients with metastatic spine tumor(s).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Metastatic Spine Tumor
Primary Tumor Research and Outcomes Network
Recruiting
This project aims to establish a network of spine oncology centers dedicated to prospective multicenter research of patients diagnosed with a primary tumor of the spine and will include a comprehensive prospective clinical database which will serve as a shared research platform. Demographic, clinical, diagnostic, and therapeutic variables will be used to answer questions about survival and local recurrence, as well as questions about adverse events (AEs), morbidity data, and health-related quali... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/19/2024
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Spinal Column Tumor
Survivor Mom Companion Comparison Study
Recruiting
The overall goal of the SMC is to help reduce posttraumatic stress symptomology for pregnant persons with a history of trauma.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/18/2024
Locations: Buffalo Prenatal-Perinatal Network, Buffalo, New York
Conditions: Posttraumatic Stress Symptom
Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1
Recruiting
This is a phase 1, dose-escalation trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with avelumab in patients with advanced solid tumors refractory to or progressing after anti-PD(L)1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Melanoma, Head and Neck Squamous Cell Carcinoma
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
Recruiting
This investigation will be conducted as an interventional intention-to-treat clinical study in a population of end stage heart failure patients who meet specific inclusion and exclusion criteria. The multi-center study will be prospective, dual-armed, non-blinded (open-label) and randomized, comparing a treatment group receiving the Jarvik 2000 LVAS with Post-Auricular Connector to an active control group treated with the PMA approved Thoratec HeartMate® II LVAS for Destination Therapy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/18/2024
Locations: Columbia/NY Presbyterian, New York, New York
Conditions: Heart Failure